Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis (Myfortic)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00997412|
Recruitment Status : Unknown
Verified October 2009 by Qualitix Clinical Research Co., Ltd..
Recruitment status was: Active, not recruiting
First Posted : October 19, 2009
Last Update Posted : October 19, 2009
|Condition or disease||Intervention/treatment||Phase|
|Myasthenia Gravis||Drug: Mycophenolic acid Drug: AZA||Not Applicable|
This will be a double-dummy study to keep the blinded quality.
- MA group: 1 tablet AZA placebo and 4 tables MA (180 mg/tab,720 mg/day) twice daily.
AZA group: 1 tablet AZA (50mg/tab) and 4 tables MA placebo twice daily.
- When patients achieve minimal manifestation (MM, i.e. complete remission), which lead to normal daily routine, the dose of pyridostigmine should reduce to 240 mg/day (4 tablets) or less. The dose of steroid should be stepped down by 10 mg qod (every other day) for every 2 weeks until the dose achieves 40 mg qod. After that, the dose should be stepped down by 5 mg qod for every month.
- When disease progresses and is no longer maintaining minimal manifestation, the dose of steroid will be stepped up by 10 mg qod for every 2 weeks until achieve clinical stable remission. The taper rule of steroid could start again 1 month after stabilization.
- Every patient will be treated for 1 year. If the patient could not achieve MM within 1 year, the blind of individual patient will be opened and the patients will be crossed over to another medical treatment. The efficacy and safety of second medication will be observed openly until the end of study.
- When the muscle weakness worsens under established study schedule, plasmapheresis could be conducted to improve the condition rapidly.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomized, Double-blind, Double-dummy Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|
|Study Start Date :||May 2009|
|Estimated Primary Completion Date :||May 2011|
|Estimated Study Completion Date :||May 2011|
MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
Drug: Mycophenolic acid
180 mg/tablet, 4 tablets twice daily
Active Comparator: AZA
AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
- The ratio of two arms patients achieve minimal manifestation (MM, i.e. complete remission) [ Time Frame: One year after treatment ]
- Osserman clinical classification [ Time Frame: One year after treatment ]
- Myasthenia gravis (MG) score [ Time Frame: One year after treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997412
|Principal Investigator:||Jiann-Horng Yeh, M.D.||Shin Kong Wu Ho-Su Memorial Hospital|